Core Viewpoint - A class action has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, during the period from June 22, 2023, to June 24, 2025 [1][2]. Allegations - The complaint alleges that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific incidents include a patient death reported on March 18, 2025, leading to a stock price drop of $27.81 per share (27.44%) to close at $73.54 [3]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, resulting in a further stock price decline of $15.24 per share (42.12%) to close at $20.91 [3]. - Following an FDA investigation announcement regarding acute liver failure risks on June 24, 2025, Sarepta's stock fell by $1.52 per share (8.01%) to close at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file a motion by August 25, 2025, but can remain absent class members without taking action [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to a halt in trials and increased regulatory scrutiny [3]. Group 2: Shareholder Actions - Shareholders who purchased shares during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - Investors who purchased Sarepta securities during the Class Period can request to be appointed as Lead Plaintiff by August 25, 2025 [2]. - The lawsuit is based on claims that Sarepta and its officers engaged in fraudulent activities [2]. Group 2: Impact of ELEVIDYS on Stock Price - On March 18, 2025, Sarepta's stock price dropped by $27.81 (27.44%) to close at $73.54 following the announcement of a death related to ELEVIDYS treatment [3]. - Following an April 4, 2025 disclosure regarding a review of the death, the stock fell by $4.18 (7.13%) to close at $54.43 [4]. - A second fatality was reported on June 15, 2025, leading to a significant stock price decline of $15.24 (42.12%) to close at $20.94 [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, causing the stock to fall by $1.52 (8.01%) to close at $17.46 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its gene therapy product, ELEVIDYS, which poses significant safety risks to patients [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from June 22, 2023, to June 24, 2025 [1]. - Allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to halted recruitment and increased regulatory scrutiny [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to potentially become lead plaintiffs [2]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of federal securities law violations related to the safety of its product ELEVIDYS, which has been linked to patient deaths and adverse events [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Sarepta, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][12]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Safety Concerns and Stock Price Impact - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, failing to disclose significant safety risks and adverse events [5]. - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [6]. - On April 4, 2025, after disclosing regulatory scrutiny and halting recruitment in clinical studies, the stock price dropped by $4.18 per share, or 7.13%, to close at $54.43 [8]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [10]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure risks associated with ELEVIDYS, resulting in a further stock price drop of $1.52 per share, or 8.01%, to close at $17.46 [10][11].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 related to the company's gene therapy product, ELEVIDYS, which has been linked to severe safety risks and adverse events [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Dolgicer v. Sarepta Therapeutics, Inc., and it involves purchasers of Sarepta securities from June 22, 2023, to June 24, 2025 [1]. - The lawsuit claims that Sarepta and its executives made false statements regarding the safety and efficacy of ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [2][3]. Group 2: Allegations and Impact - Allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to regulatory scrutiny and halt of clinical trials [3]. - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, causing a stock price drop of over 27% [4]. - Following further disclosures about patient deaths and regulatory actions, Sarepta's stock experienced additional declines of more than 7% and 42% on subsequent dates [5][6]. - On June 24, 2025, the FDA announced an investigation into the risks associated with ELEVIDYS, resulting in an 8% drop in stock price [7]. Group 3: Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [8]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [8]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [9][10]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history at $7.2 billion [10].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, regulatory scrutiny, and increased risk regarding the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Allegations and Safety Concerns - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during trial protocols [2]. - It is alleged that the severity of adverse events from ELEVIDYS treatment led to the halting of recruitment and dosing in clinical trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [2]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 25, 2025, with the option to remain an absent class member if they choose not to take action [5].

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...